Back

Safety and immunogenicity of a third dose of COVID-19 protein subunit vaccine (CovovaxTM) after homologous and heterologous two-dose regimens

2022-09-09 allergy and immunology Title + abstract only
View on medRxiv
Show abstract

ObjectiveTo report the safety and immunogenicity profile of a protein subunit vaccine (Covovax) given as a third (booster) dose to individuals primed with different primary vaccine regimens. MethodsIndividuals primed with two doses of COVID-19 vaccines for at least 3 months were enrolled and assigned to five groups according to their primary vaccine regimens: CoronaVac, BBIBP-CorV, AZD1222, BNT162b2, and CoronaVac/AZD1222. Immunogenicity analysis was performed to determine binding antibodies, n...

Predicted journal destinations